Abvc Biopharma, Inc. ABVC
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Abvc Biopharma, Inc. (ABVC) is a healthcare company listed in the US with a market value of about $25M. In fiscal year 2025 it had revenue of $296000 and net income of -$8M, a net margin of -2671.8%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -9% a year, a 5-year average ROIC of -138%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Abvc Biopharma
Abvc Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $50M in 2015 to $296000 in 2025, a decline of about 40.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 535% over three years (dilution for shareholders). It spends 41% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296000 | $509589 | $152430 | $969783 | $355797 | $483045 | $701719 | $6956 | — | — |
| Net income | -$8M | -$5M | -$8M | -$16M | -$13M | -$11M | -$4M | -$6M | -$4M | -$11M |
| Free cash flow | — | — | -$4M | -$8M | -$8M | — | — | — | — | — |
| EPS (diluted) | $-0.39 | $-0.42 | $-1.80 | $-5.19 | $-5.10 | $-5.00 | $-2.10 | $-0.20 | $-0.20 | $-0.60 |
| Net margin | -2671.8% | -962.1% | -5109.3% | -1693.5% | -3608.5% | -2193.1% | -560.5% | -87184.2% | — | — |
| ROIC | -41.0% | -170.2% | -163.8% | -229.4% | -85.4% | -154.8% | -147.0% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Abvc Biopharma stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Abvc Biopharma pay a dividend?
Not currently.
Is Abvc Biopharma a good stock to buy?
We do not give buy or sell advice. Abvc Biopharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.